Onward Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$27.5M
- Investors
-
10
Onward Therapeutics General Information
Description
Operator of an oncology company intended to develop breakthrough medicines for the treatment of cancer. The company provides optimized cell therapy products consisting of highly activated and alloreactive allogeneic natural killer (NK) cells, enhancing tumor selectivity and cell signaling interference, enabling medical professionals to use bispecific antibodies for immuno-oncology to treat cancer patients.
Contact Information
Website
www.onward-therapeutics.comCorporate Office
- 2F, Number 60, Songjiang Road
- Zhongshan District
- Taipei
- Taiwan
Corporate Office
- 2F, Number 60, Songjiang Road
- Zhongshan District
- Taipei
- Taiwan
Onward Therapeutics Timeline
Onward Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 17-Nov-2026 | $27.5M | Completed | Clinical Trials - Phase 1 | ||
| 2. Later Stage VC (Series B1) | Cancelled | Clinical Trials - Phase 1 | ||||
| 1. Later Stage VC (Series A) | 02-Aug-2024 | $84.8M | $84.8M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Onward Therapeutics Signals
Onward Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bailey Biofund | Venture Capital | Minority | ||
| Chlitina | Corporation | Minority | ||
| Everbright Biofund | Venture Capital | Minority | ||
| Grand Fortune Capital (HK) Company | Asset Manager | Minority | ||
| Hercules Bioventure Partners Taiwan | Venture Capital | Minority |
Onward Therapeutics Investments & Acquisitions (2)
Onward Therapeutics’s most recent deal was a Merger/Acquisition with EMERCell. The deal was made on 17-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| EMERCell | 17-Feb-2021 | Merger/Acquisition | Drug Discovery | ||
| Biomunex Pharmaceuticals | 16-Feb-2021 | Later Stage VC | Drug Discovery |
Onward Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| EMERCell | Paris, France | 2013 |
Onward Therapeutics FAQs
-
When was Onward Therapeutics founded?
Onward Therapeutics was founded in 2019.
-
Where is Onward Therapeutics headquartered?
Onward Therapeutics is headquartered in Taipei, Taiwan.
-
What is the size of Onward Therapeutics?
Onward Therapeutics has 13 total employees.
-
What industry is Onward Therapeutics in?
Onward Therapeutics’s primary industry is Drug Discovery.
-
Is Onward Therapeutics a private or public company?
Onward Therapeutics is a Private company.
-
What is Onward Therapeutics’s current revenue?
The current revenue for Onward Therapeutics is .
-
How much funding has Onward Therapeutics raised over time?
Onward Therapeutics has raised $112M.
-
Who are Onward Therapeutics’s investors?
Bailey Biofund, Chlitina, Everbright Biofund, Grand Fortune Capital (HK) Company, and Hercules Bioventure Partners Taiwan are 5 of 10 investors who have invested in Onward Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process